Tempest Therapeutics jumps after-hours on Hebei Senlang option deal
Tempest Therapeutics (TPST) rose about 66% after-hours to $1.26 following an exclusive option deal with Hebei Senlang. The company said its dose-escalation trial showed no Grade 3+ cytokine release syndrome or ICANS as of Aug 25.
Tempest Therapeutics, Inc. 26 on surging volume after it announced an exclusive option deal with Hebei Senlang. The company also said its dose-escalation trial showed no Grade 3+ cytokine release syndrome or ICANS as of Aug 25, supporting continued escalation and enrollment.